Ph I Trial of Cell Based Therapy for DMD

General Information
Summary	This is a single-center, single-arm, interventional phase 1 trial to evaluate the safety and tolerability of local injection of induced pluripotent stem cell (iPSC)- derived CD54+ allogeneic muscle progenitor cells in individuals with Duchenne muscular dystrophy (DMD)
Clinical trials phase	Phase 1
Start date (estimated)	2024-12-16
End date (estimated)	2027-03-03
Clinical feature	Label Duchenne muscular dystrophy Link http://purl.obolibrary.org/obo/DOID_11723 Description A muscular dystrophy that has_material_basis_in X-linked mutations in the DMD gene found on the X chromosome. It is characterized by rapidly progressing muscle weakness and muscle atrophy initially involving the lower extremities and eventually affecting the whole body. It affects males whereas females can be carriers. The symptoms start before the age of six and may appear at infancy.; OMIM mapping confirmed by DO. [SN].
Administrative Information
NCT number	NCT06692426
ICTRP weblink	https://trialsearch.who.int/Trial2.aspx?TrialID=NCT06692426
Other study identifiers	Name 2021LS140
Source weblink	https://clinicaltrials.gov/study/NCT06692426
Regulatory body approval	Name Food and Drug Administration (FDA) Country United States
Public contact	Email mdstemcell@umn.edu Public email mdstemcell@umn.edu First name Peter Last name Kang Phone +1 612-624-9452
Sponsors	Masonic Cancer Center, University of Minnesota
Collaborators	Duchenne UK Parent Project Muscular Dystrophy
Cells
Recruitment
Recruitment Status	Not yet recruiting
Estimated number of participants	8